Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.

Some existing medicines show promise as safe treatments to protect against the side effects of radiation therapy.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Finasteride, often used for hair loss, can potentially cause cataracts.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

mTOR may link different pathways in hair follicle tumor formation.

Cytarabine can cause multiple organ toxicities, especially neurotoxicity, but better research methods are needed to fully understand and predict these effects.

Serenoa repens extract shows promise as a natural treatment for prostate cancer.

Renal transplant recipients often have skin issues, especially infections, and need regular skin check-ups.

Spontaneous keloids may be linked to nephrogenic systemic fibrosis in dialysis patients.

Hair growth-promoting nutraceuticals do not block the cancer-fighting effects of tamoxifen and may enhance its action.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.